Ownership Submission
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  TREPPEL JERRY
2. Date of Event Requiring Statement (Month/Day/Year)
12/01/2008
3. Issuer Name and Ticker or Trading Symbol
ELITE PHARMACEUTICALS INC /DE/ [ELTP:US]
(Last)
(First)
(Middle)
C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVENUE
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
11/06/2008
(Street)

NORTHVALE, NJ 07647
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option (1)   (2) 12/01/2018 Common Stock 180,000 $ 0.06 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
TREPPEL JERRY
C/O ELITE PHARMACEUTICALS, INC.
165 LUDLOW AVENUE
NORTHVALE, NJ 07647
  X      

Signatures

/s/ Jerry Treppel 07/01/2009
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This Form 3 amends the Form 3 filed with the U.S. Securities and Exchange Commission on November 6, 2008 (the "Original Form 3"). In the Original Form 3, 180,000 shares of the Registrant's common stock, par value $0.01 per share (the "Common Stock"), were reported under Table I as "Non-Derivative Securities" beneficially owned by the Reporting Person, however, such shares actually represent shares underlying an option granted by the Registrant to the Reporting Person pursuant to a Non-Qualified Stock Option Agreement, dated December 1, 2008. Accordingly, the Original Form 3 is hereby amended to report the aforesaid option, and the 180,000 shares of Common Stock underlying such option, under Table II as "Derivative Securities." The Original Form 3 has not been amended in any way except as expressly provided herein.
(2) The option vests according to the following schedule: (1) 60,000 shares of Common Stock underlying the option vested on December 1, 2008; (2) an additional 60,000 shares of Common Stock underlying the option shall vest on the date immediately following the date of the next annual meeting of the stockholders of the Registrant (the "Annual Meeting") following the option grant date; and (3) the remaining 60,000 shares of Common Stock underlying the option shall vest on the date immediately following the one year anniversary of the Annual Meeting; provided, however, that the option shall fully vest upon the Reporting Person's death, disability, retirement as a director or removal as a director without cause at the request of the Registrant's Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.